Neoadjuvant Therapy for Stage IIIA HER2-Positive Breast Cancer
Introduction to HER2-Positive Breast Cancer
- Invasive ductal carcinoma accounts for 85-90% of all invasive breast cancers, with HER2-positive disease comprising approximately 15-20% of cases, according to the National Comprehensive Cancer Network 1
- HER2-positive breast cancer represents a distinct biologic subtype with specific therapeutic implications, confirmed by immunohistochemistry showing 3+ staining or gene amplification by FISH 1
Neoadjuvant Therapy Rationale
- Primary systemic therapy is indicated for locally advanced breast cancer (stage IIIA, IIIB, IIIC) and represents an alternative for large operable breast cancer to allow breast-conserving surgery 3
- For HER2-positive tumors, anthracycline-based chemotherapy regimens incorporating trastuzumab are recommended 2
Treatment Approach
- The American College of Surgeons and other guideline societies recommend neoadjuvant chemotherapy for stage IIIA breast cancer to potentially downsize the tumor and increase likelihood of successful surgical resection 2
- Neoadjuvant chemotherapy allows for assessment of tumor response to systemic therapy in vivo, potential downstaging to allow less extensive surgery, and early treatment of micrometastatic disease 3 2
Radiation Therapy
- Post-mastectomy radiation therapy to the chest wall and regional lymph nodes is strongly recommended for patients with T3N1M0 disease who undergo mastectomy 2
- Radiation therapy should include chest wall irradiation, supraclavicular lymph node field, and strong consideration for internal mammary lymph node inclusion 2
Endocrine Therapy
- For hormone receptor-positive disease (ER+/PR+), endocrine therapy is recommended following completion of chemotherapy 2 4
- Tamoxifen for 5-10 years is the preferred initial approach for premenopausal women 4
Follow-up and Surveillance
- Recommended follow-up includes clinical examination every 4-6 months for the first 5 years, then annually, and annual mammography of the contralateral breast 2
- Cardiac monitoring should continue with LVEF measurements every 3 months during trastuzumab therapy and every 6 months for at least 2 years following completion 2